Background: Using recombinant tissue plasminogen activator (rt-PA) during the first 3 h up to 6 h of stroke was allowed to reduce the poor functional consequences of stroke. Objectives: assess the effects of intravenous dosage of rt-PA during the first 6 h after on early and late outcomes of acute ischemic stroke (AIS). Methods: all studies regarding the intravenous rt-PA given within 6 h of onset of acute ischemic stroke up to 2016 were searched the outcomes, and the mortality rates were evaluated at the final follow up.
INTRODUCTION
Acute ischemic stroke (AIS) is a worldwide cause of disability and death accounting about 87% of the stroke cases. The occlusion of the arteries causes blood deprivation and cell death associated with neural dysfunction . The most effective treatment for AIS is intravenous thrombolysis which could reverse the arterial occlusion and decrease the number of damaged cells as well as improving the recovery and decreasing the rates of death. Another advantage of using intravenous thrombolysis during the early period of stroke would result in significant improving in the neurological functions (3, 4) . Using recombinant tissue plasminogen activator (rt-PA) during the first 3 h up to 6 h of stroke was allowed in patients younger than 80 years (5, 6) . Also, other studies showed that after 6 h the treatment with rt-PA could result in reducing the poor functional consequences of stroke (7, 8) . There is increasing evidence regarding treating the AIS with rt-PA after 6 hours, however, other factors would affect the outcomes including previous chronic diseases including hypertension, heart diseases and diabetes, stroke severity, subtypes and previous usage of antiplatelet drugs (9, 10) . This is a systemic review conducted to assess the effects of intravenous dosage of rt-PA during the first 6 h after on early and late outcomes of AIS.
METHODS

Information sources and search strategy
The electronic database search included 1995 to 2016, Data extraction and quality assessment. Using predetermined forms, data were extracted independently by two authors. Data were collected on study design and conduct, country of study, sample size, and outcome.
From each study, outcome data were extracted in 2x2 tables or using the mean and SD. Study quality assessment was performed using QUADAS-2 (Quality Assessment for Diagnostic Accuracy Studies-2: A Revised Tool) for evaluating the diagnostic accuracy of studies (11) . The tool consists of four key domains covering patient selection, index test(s), reference standard, the flow and timing. Each domain was assessed in terms of risk of bias, and the first three domains were also assessed for concerns regarding applicability. Signaling questions were included in the tool to help judge the risk of bias. The index test(s) for the included studies were the biomarkers and the reference standard.
Inclusion Criteria
The inclusion criteria for the systematic review were all prospective studies with use of Tissue Plasminogen Activator for Acute Ischemic Stroke. Exclusion criteria were retrospective studies, case reports, case series, letters, and reviews; studies that did not include tissue plasminogen activator as a treatment. Studies in 1122 languages other than English were also excluded where no translated version of the manuscript was available. The studies included in the research met the following criteria including: (1) English studies during the last 20 years, (2) patients with ischemic stroke older than 18 years old, (3) patients who were treated with rt-PA during the first 6 h after stroke, (4) evaluating the outcomes after administration.
Outcomes
The outcomes and efficiency of intravenous rt-PA were assessed from the included studies including the early outcome during the first week, degree of disability, safety outcomes and mortality rates.
Statistical analysis
Statistical analysis was performed using the Cochrane systematic reviews(Review Manager 5.3) and the meta-analysis of the eligible studies performed using the diagnostic test accuracy review stream (12) . Data from each primary study were summarized in a 2x2 table of test results and forest plots constructed showing within-study estimates and confidence interval. The study was done after approval of ethical board of Northern Border university.
RESULTS
The primary search strategy included 127 papers from which 61 papers met the criteria after removing the duplicates than 20 papers were excluded after reviewing the abstract. Only 41 full texts were eligible from which 20 were excluded for different types of studies then 21 studies were included into qualitative study while 6 were excluded for their specificity and finally 15 studies were included (Fig. 1) . The main characteristics of the studies were shown at Table (1). Quantitative data summary and synthesis
Data were summarized for three outcomes, symptomatic intracranial hemorrhage, favorable functional outcome and mortality. Table ( 2), shows the relationship between IV-tPA and favorable functional outcome at first 10 hours, it was found that there was a significant increase in functional outcome by using IV-tPA significantly (p <0.01) ( Figure. 3). Table ( 3), shows the relationship between IV-tPA symptomatic intracranial hemorrhage, it was found that there was a significant decrease in intracranial hemorrhage in the patients treated with IV-tPA (Figure. 5). Table ( 4) , shows the relationship between IV-tPA dose and mortality at end of follow up, it was found that there was a significant decrease in the mortality rate in patients treated with IV-tPA ( Figure. 7) .
Publication Bias
Visual inspection of the funnel plot did not identify substantial asymmetry (Fig. 2, 4 and 6). The funnel plot indicated evidence of publication bias among studies concerning favorable functional outcome. 
DISCUSSION
This systemic review and meta-analysis showed that the favorable functional outcome at first 10 hours were significantly increased among patients who administrated IV-tPA significantly (p <0.01) showing that most of subjects had minimal or no disability after IVtPA (21) . Also, rt-PA use was related significantly with improvement of the neurological pain and good functional outcome (14, 19) .Over that low dose versus standard dose showed favorable outcomes, lower mortality rates and low level of intracranial hemorrhage (17) . Most of the studies showed that the risks of intracranial hemorrhage are decreased after 1129 using rt-PA and this was also presented in other studies (14, 18, 20) . Also, there was no association between the use of rt-PA and risk of hemorrhagic complications in many cohorts (19) . As for the mortality rate, the use of rt-PA was negatively associated with in-hospital mortality after adjusting the multiple confounding factors (19) . Other studies showed the same respect of results (18, 21) . This review also highlights the benefits of using rt-PA during the first 6 hours after symptoms which showed that lower levels of death occurred during the follow up period in which patients who survive without hemorrhage will benefit from the effects of rt-PA. Also, rt-PA has many favorable outcomes which may balance the outcomes of using the treatment and reduce the death for long term periods. The longer follow-up in some studies showed that the benefits of using rt-PA may balance its hazards especially in severe strokes thus delaying the treatment would result in unfavorable outcomes particularly among older people.
CONCLUSION
The study indicated that using intravenous rt-PA could increase the number of living patients with favorable outcome, less disabilities and intracranial hemorrhage among acute ischaemic stroke patients during the first 6 hours.
